Publications by authors named "S Kotagiri"
Article Synopsis
- Scientists found mutations in some important parts of a protein complex related to lung cancer.
- They created a new drug called YD23 that targets a specific part of this complex to help fight cancer cells.
- Testing showed that YD23 can slow down tumor growth in cells that have the mutations, which could help develop better treatments for certain lung cancers.
Cancer genomic studies have identified frequent mutations in subunits of the SWI/SNF chromatin remodeling complex including in non-small cell lung cancer with a frequency of up to 33% in advanced stage disease, making it the most frequently mutated complex in lung cancer. We and others have identified to be synthetic lethal to indicating SMARCA2 is a high value therapeutic target. Here, we disclose the discovery and characterization of potent, selective and orally bioavailable Cereblon-based SMARCA2 PROTACs.
View Article and Find Full Text PDFArticle Synopsis
- Scientists found that certain lung cancers with changes in a specific protein mix called SWI/SNF don’t respond well to a type of treatment called immunotherapy.
- They used mice with these lung cancers to study why the treatment doesn't work, discovering that the cancer cells were stopping immune cells from getting to the tumor.
- The researchers learned that this happened because the cancer cells changed how important signals in the body were working, making it hard for immune cells to help fight the cancer.
Lung cancer screening via annual low-dose computed tomography has poor adoption. We conducted a prospective case-control study among 958 individuals eligible for lung cancer screening to develop a blood-based lung cancer detection test that when positive is followed by a low-dose computed tomography. Changes in genome-wide cell-free DNA fragmentation profiles (fragmentomes) in peripheral blood reflected genomic and chromatin characteristics of lung cancer.
View Article and Find Full Text PDFIntroduction: Lutein (L) and zeaxanthin (Z) are carotenoids that are found in the macula of the human eye and are known to improve visual functions. However, poor bioavailability of supplemental L and Z poses a challenge to achieving significant benefits after consumption. We developed a novel patented formulation of L and Z (Ocusorb) and demonstrated the improved bioavailability in a pharmacokinetic clinical study.
View Article and Find Full Text PDF